Vanina de Verneuil - Oct 1, 2024 Form 3 Insider Report for Vir Biotechnology, Inc. (VIR)

Signature
/s/ Vanina de Verneuil
Stock symbol
VIR
Transactions as of
Oct 1, 2024
Transactions value $
$0
Form type
3
Date filed
10/2/2024, 12:07 PM
Next filing
Nov 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding VIR Common Stock 65.1K Oct 1, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VIR Stock Option (Right to Buy) Oct 1, 2024 Common Stock 58K $39.31 Direct F1
holding VIR Stock Option (Right to Buy) Oct 1, 2024 Common Stock 17K $29.48 Direct F2
holding VIR Stock Option (Right to Buy) Oct 1, 2024 Common Stock 30K $27.01 Direct F3
holding VIR Stock Option (Right to Buy) Oct 1, 2024 Common Stock 30K $10.04 Direct F4
holding VIR Stock Option (Right to Buy) Oct 1, 2024 Common Stock 45K $10.11 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the stock option vested and became exercisable on December 21, 2021, and the remainder vest in 36 equal monthly installments thereafter.
F2 25% of the shares subject to the stock option vested and became exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.
F3 25% of the shares subject to the stock option vested and became exercisable on February 22, 2024, and the remainder vest in 36 equal monthly installments thereafter.
F4 25% of the shares subject to the stock option vest and become exercisable on November 1, 2024, and the remainder vest in 36 equal monthly installments thereafter.
F5 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter.